Literature DB >> 9271202

Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons.

J R Muñoz-Montaño1, F J Moreno, J Avila, J Diaz-Nido.   

Abstract

In Alzheimer's disease, tau protein becomes hyperphosporylated, which can contribute to neuronal degeneration. However, the implicated protein kinases are still unknown. Now we report that lithium (an inhibitor of glycogen synthase kinase-3) causes tau dephosphorylation at the sites recognized by antibodies Tau-1 and PHF-1 both in cultured neurons and in vivo in rat brain. This is consistent with a major role for glycogen synthase kinase-3 in modifying proline-directed sites on tau protein within living neurons under physiological conditions. Lithium also blocks the Alzheimer's disease-like proline-directed hyperphosphorylation of tau protein which is observed in neurons treated with a phosphatase inhibitor. These data raise the possibility of using lithium to prevent tau hyperphosphorylation in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9271202     DOI: 10.1016/s0014-5793(97)00688-1

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  71 in total

Review 1.  Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.

Authors:  M Goedert
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

2.  Hyperactivation of mitogen-activated protein kinase increases phospho-tau immunoreactivity within human neuroblastoma: additive and synergistic influence of alteration of additional kinase activities.

Authors:  F J Ekinci; T B Shea
Journal:  Cell Mol Neurobiol       Date:  1999-04       Impact factor: 5.046

Review 3.  Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects.

Authors:  Jorge A Quiroz; Rodrigo Machado-Vieira; Carlos A Zarate; Husseini K Manji
Journal:  Neuropsychobiology       Date:  2010-05-07       Impact factor: 2.328

4.  NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy.

Authors:  Raquel Gómez-Sintes; José J Lucas
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

5.  Regulation of GSK3 isoforms by phosphatases PP1 and PP2A.

Authors:  Félix Hernández; Elena Langa; Raquel Cuadros; Jesús Avila; Nieves Villanueva
Journal:  Mol Cell Biochem       Date:  2010-07-22       Impact factor: 3.396

6.  Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo.

Authors:  Wendy Noble; Emmanuel Planel; Cindy Zehr; Vicki Olm; Jordana Meyerson; Farhana Suleman; Kate Gaynor; Lili Wang; John LaFrancois; Boris Feinstein; Mark Burns; Pavan Krishnamurthy; Yi Wen; Ratan Bhat; Jada Lewis; Dennis Dickson; Karen Duff
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-02       Impact factor: 11.205

Review 7.  Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.

Authors:  Richard S Jope; Myoung-Sun Roh
Journal:  Curr Drug Targets       Date:  2006-11       Impact factor: 3.465

Review 8.  Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease.

Authors:  Zhao Zhong Chong; Faqi Li; Kenneth Maiese
Journal:  Brain Res Brain Res Rev       Date:  2005-01-08

9.  Lithium prevents acrolein-induced neurotoxicity in HT22 mouse hippocampal cells.

Authors:  Yingjuan Huang; Jian Qin; Meihui Chen; Xiaojuan Chao; Ziwei Chen; Charles Ramassamy; Rongbiao Pi; Minghua Jin
Journal:  Neurochem Res       Date:  2014-02-13       Impact factor: 3.996

10.  Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein.

Authors:  Charbel E-H Moussa
Journal:  J Mol Neurosci       Date:  2008-06-17       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.